ANI Pharmaceuticals (NASDAQ:ANIP) “Overweight” Rating Reconfirmed Today By Cantor Fitzgerald; The Price Target is $74

August 9, 2018 - By Billy Entrekin

Investors sentiment increased to 1.43 in Q1 2018. Its up 0.34, from 1.09 in 2017Q4. It increased, as 12 investors sold ANI Pharmaceuticals, Inc. shares while 42 reduced holdings. 37 funds opened positions while 40 raised stakes. 6.72 million shares or 7.48% more from 6.25 million shares in 2017Q4 were reported.

Legal General Grp Public Limited Co has invested 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Trexquant Invest Limited Partnership reported 3,526 shares. 27,800 were accumulated by Mackay Shields Limited Com. Manufacturers Life Ins The has invested 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Bank Of America De holds 0% or 8,833 shares. Argent Llc holds 18,145 shares. Aqr Ltd Co stated it has 0% of its portfolio in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Kbc Grp Nv has 0.01% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Clearbridge Invests Ltd Limited Liability Company, a New York-based fund reported 25 shares. 1492 Cap Management Ltd Liability Corporation holds 36,321 shares or 1.63% of its portfolio. Gsa Prtn Limited Liability Partnership holds 0.02% or 7,100 shares. Loomis Sayles Lp holds 0% or 108 shares in its portfolio. 29,500 are owned by Virginia Retirement Et Al. Art Advsr Limited Liability has 0.06% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Regions Fin Corp has 11 shares for 0% of their portfolio.

Since March 1, 2018, it had 0 insider buys, and 10 insider sales for $18.16 million activity. RAYNOR DANIEL had sold 7,215 shares worth $439,047 on Thursday, March 15. 33,200 shares were sold by MARSHBANKS TRACY, worth $2.06M. The insider PRZYBYL ARTHUR sold $1.47M. $1.77M worth of stock was sold by Schrepfer Robert W on Thursday, March 1.

ANI Pharmaceuticals (NASDAQ:ANIP) Rating Reaffirmed

They currently have a $74 price target on ANI Pharmaceuticals (NASDAQ:ANIP). The target price by Cantor Fitzgerald would suggest a potential upside of 29.69 % from the company’s stock close price. This has been disclosed to clients in analysts note on 8 August.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Ratings Coverage

Among 2 analysts covering ANI Pharmaceuticals (NASDAQ:ANIP), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ANI Pharmaceuticals has $8500 highest and $74 lowest target. $78’s average target is 36.70% above currents $57.06 stock price. ANI Pharmaceuticals had 3 analyst reports since February 28, 2018 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald on Wednesday, August 8 with “Overweight”. The firm earned “Buy” rating on Monday, June 11 by Cantor Fitzgerald. The stock has “Buy” rating by Canaccord Genuity on Wednesday, February 28.

The stock increased 1.10% or $0.62 during the last trading session, reaching $57.06. About 288,123 shares traded or 179.49% up from the average. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has risen 31.37% since August 9, 2017 and is uptrending. It has outperformed by 18.80% the S&P500.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and markets branded and generic prescription pharmaceuticals in the United States. The company has market cap of $672.53 million. It focuses on producing controlled substances, anti-cancer , hormones and steroids, and complex formulations. It has a 14265 P/E ratio. The firm offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis.

More notable recent ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) news were published by: Benzinga.com which released: “64 Stocks Moving In Tuesday’s Mid-Day Session” on August 07, 2018, also Benzinga.com with their article: “77 Biggest Movers From Yesterday” published on August 08, 2018, Benzinga.com published: “10 Biggest Price Target Changes For Wednesday” on August 08, 2018. More interesting news about ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) were released by: Seekingalpha.com and their article: “ANI Pharmaceuticals’ (ANIP) CEO Arthur Przybyl on Q2 2018 Results – Earnings Call Transcript” published on August 07, 2018 as well as Streetinsider.com‘s news article titled: “ANI Pharma (ANIP) Misses Q2 EPS by 21c, Updates Guidance” with publication date: August 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.